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tients a lower body mass index and a decrease in body weight are
associated with worse outcome (4). Treatments that are clearly
beneficial in CHF have also been shown to prevent weight loss
(angiotensin-converting enzyme inhibitors and beta-blockers [4])
or even increased body fat mass (beta-blockers) (5). Until today
there are no data on changes in body weight or body composition
following CRT. We agree with Bax et al. (1) that much more
research remains to be done regarding CRT. We believe that
metabolic pathways should be an important focus of these inves-
tigations. This will promote our understanding of the pathophys-
iology of CHF and of the response to CRT and may help to better
guide patient selection for cardiac resynchronization therapy.
*Tim Karhausen
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REPLY
We thank Dr. Karhausen and colleagues for their constructive
comments concerning our manuscript of the unresolved issues in
cardiac resynchronization therapy (CRT) (1). As the researchers
point out, there are many such issues concerning CRT. The most
difficult issue remains the prediction of response to CRT (2). It has
become evident that the current selection criteria are not sufficient,
as 20% to 30% of patients do not respond to CRT. The most
promising techniques to better select the potential responders are
the different sophisticated tissue Doppler imaging (TDI) tech-
niques. However, as pointed out in part 1 of our review on CRT
(2), many techniques have been proposed. In total, 24 studies with
TDI to predict response to CRT have been published; only 2 (8%)
demonstrated that interventricular dyssynchrony was useful to
predict response, whereas all 24 studies demonstrated some value
of intraventricular (within the left ventricle) dyssynchrony for the
prediction of response to CRT. How to precisely assess the
intraventricular dyssynchrony is currently not clear, and the extent
of dyssynchrony (in ms) needed to result in response to CRT is
also uncertain.
Moreover, this uncertainty is further complicated by the fact
that a precise definition of a responder to CRT is lacking. As
emphasized by Dr. Karhausen and colleagues, various end points
have been used. In addition, a single patient may show improve-
ment in a certain end point, but not in another end point. This has
been highlighted recently by Bleeker et al. (3) showing a discrep-
ancy between improvement in clinical markers and echocardio-
graphic markers in patients undergoing CRT.
Finally, Dr. Karhausen and colleagues raise an even more
complicated issue, namely changes in metabolic status after CRT.
Indeed, this is a very important concern, and data on this topic are
virtually nonexistent. We fully agree with Dr. Karhausen and
colleagues that more work is needed, including in the field of
metabolic response to CRT.
*Jeroen J. Bax, MD, PhD
*Department of Cardiology
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Allergic Reactions Following
Implantation of Drug-Eluting Stents:
A Manifestation of Kounis Syndrome?
In the very interesting study (1) and editorial (2) published in the
January 3, 2006 issue of the Journal, the investigators reported and
commented on 17 patients who developed allergic reactions after
implantation of drug-eluting stents (DES). These reactions in-
cluded rash, hives, itching, dyspnea, and fever. However, four
patients developed in-stent thrombosis and died at 4, 5, 18, and 18
months after implantation, respectively. Eosinophilia and elevated
immunoglobulin E (IgE) titers accompanied the allergic reactions.
One patient had implanted a TAXUS (Boston Scientific Corp.,
Natick, Massachusetts) stent impregnated with the antineoplastic
agent paclitaxel, and the other three had CYPHER (Cordis Corp.,
Miami Lakes, Florida) stents impregnated with the anti-
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